Somatic mutations of BAI1 and its family members BAI2 and BAI3, which encode brain-specific angiogenesis inhibitors, have been identified in several cancers, including breast cancer, lung cancer, and ovarian cancer. This evidence concerns the gene ADGRB2 and breast carcinoma.